iRhythm Technologies, Inc. - Common Stock (IRTC)

Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 5.9%. This performance was discouraging since the S&P 500 held steady.

Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest of the patient monitoring stocks fared in Q4.

The company is facing a regulatory setback. But one analyst doesn't expect that to impact its upcoming, potential approval.

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom (NASDAQ:DXCM).

Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 24% year on year to $164.3 million. The company expects the full year’s revenue to be around $680 million, close to analysts’ estimates. Its non-GAAP profit of $0.01 per share was significantly above analysts’ consensus estimates.

Medical technology company iRhythm Technologies (NASDAQ:IRTC) will be announcing earnings results tomorrow afternoon. Here’s what investors should know.

The next wave of AI will include interactive and autonomous AI and these three companies are making inroads into these areas today

Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?

FDA approves iRhythm's 510(k) submission for Zio AT device. A second approval may come soon, enhancing the company's mobile cardiac telemetry services.